Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations

by Neumann, M, Heesch, S, Gökbuget, N, Schwartz, S, Schlee, C, Benlasfer, O, Farhadi-Sartangi, N, Thibaut, J, Burmeister, T, Hoelzer, D, Hofmann, W-K, Thiel, E, Baldus, C D
Published 2012

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

by Zugmaier, G, Topp, M S, Alekar, S, Viardot, A, Horst, H-A, Neumann, S, Stelljes, M, Bargou, R C, Goebeler, M, Wessiepe, D, Degenhard, E, Gökbuget, N, Klinger, M
Published 2014

FAT1 expression and mutations in adult acute lymphoblastic leukemia

by Neumann, M, Seehawer, M, Schlee, C, Vosberg, S, Heesch, S, von der Heide, E K, Graf, A, Krebs, S, Blum, H, Gökbuget, N, Schwartz, S, Hoelzer, D, Greif, P A, Baldus, C D
Published 2014

Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL

by Fransecky, L., Neumann, M., Heesch, S., Schlee, C., Ortiz-Tanchez, J., Heller, S., Mossner, M., Schwartz, S., Mochmann, L. H., Isaakidis, K., Bastian, L., Kees, U. R., Herold, T., Spiekermann, K., Gökbuget, N., Baldus, C. D.
Published 2016

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

by Gökbuget, N, Kelsh, M, Chia, V, Advani, A, Bassan, R, Dombret, H, Doubek, M, Fielding, A K, Giebel, S, Haddad, V, Hoelzer, D, Holland, C, Ifrah, N, Katz, A, Maniar, T, Martinelli, G, Morgades, M, O'Brien, S, Ribera, J-M, Rowe, J M, Stein, A, Topp, M, Wadleigh, M, Kantarjian, H
Published 2016